1. Home
  2. KE vs BLSM Comparison

KE vs BLSM Comparison

Compare KE & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimball Electronics Inc.

KE

Kimball Electronics Inc.

N/A

Current Price

$20.05

Market Cap

462.1M

Sector

Technology

ML Signal

N/A

Logo BlossomHill Therapeutics Inc. Common Stock

BLSM

BlossomHill Therapeutics Inc. Common Stock

N/A

Current Price

$15.48

Market Cap

483.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
KE
BLSM
Founded
1961
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
462.1M
483.4M
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
KE
BLSM
Price
$20.05
$15.48
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$33.50
★ $35.40
AVG Volume (30 Days)
★ 184.9K
146.7K
Earning Date
11-04-2026
11-23-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 66.18
N/A
EPS
★ 0.11
N/A
Revenue
★ $1,431,378,000.00
N/A
Revenue This Year
$7.87
N/A
Revenue Next Year
$4.18
N/A
P/E Ratio
$178.82
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$19.10
$11.02
52 Week High
$32.00
$27.99

Technical Indicators

Market Signals
Indicator
KE
BLSM
Relative Strength Index (RSI) 31.31 50.53
Support Level N/A $12.93
Resistance Level $27.09 $17.53
Average True Range (ATR) 1.43 1.76
MACD -0.75 0.27
Stochastic Oscillator 11.68 67.67

Price Performance

Historical Comparison
KE
BLSM

About KE Kimball Electronics Inc.

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.

About BLSM BlossomHill Therapeutics Inc. Common Stock

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Share on Social Networks: